Incyte Corporation (NASDAQ:INCY) EVP Barry P. Flannelly sold 714 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $124.25, for a total value of $88,714.50. Following the sale, the executive vice president now directly owns 15,496 shares of the company’s stock, valued at $1,925,378. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Incyte Corporation (NASDAQ INCY) traded down 0.51% during midday trading on Friday, reaching $119.15. The company’s stock had a trading volume of 2,995,901 shares. The stock’s market capitalization is $24.51 billion. Incyte Corporation has a 12 month low of $79.75 and a 12 month high of $153.15. The stock’s 50 day moving average is $127.79 and its 200 day moving average is $130.32.

Incyte Corporation (NASDAQ:INCY) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.01). Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The firm had revenue of $326.40 million for the quarter, compared to the consensus estimate of $318.45 million. During the same period in the previous year, the firm earned $0.18 EPS. Incyte Corporation’s revenue for the quarter was up 32.5% on a year-over-year basis. On average, analysts forecast that Incyte Corporation will post ($0.84) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/15/insider-selling-incyte-corporation-incy-evp-sells-714-shares-of-stock.html.

Several analysts have commented on INCY shares. Morgan Stanley reaffirmed an “overweight” rating and set a $142.00 price objective on shares of Incyte Corporation in a research note on Friday, May 19th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $149.00 price objective on shares of Incyte Corporation in a research note on Thursday, August 31st. Jefferies Group LLC reaffirmed a “buy” rating and set a $148.00 price objective on shares of Incyte Corporation in a research note on Thursday, May 18th. Zacks Investment Research raised Incyte Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, May 23rd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $172.00 price objective on shares of Incyte Corporation in a research note on Monday, August 28th. Eight analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $142.16.

Hedge funds and other institutional investors have recently bought and sold shares of the business. D. Scott Neal Inc. bought a new position in shares of Incyte Corporation in the second quarter valued at $103,000. Tower Research Capital LLC TRC bought a new position in shares of Incyte Corporation in the first quarter valued at $105,000. Cornerstone Advisors Inc. increased its holdings in shares of Incyte Corporation by 19.6% in the second quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 145 shares in the last quarter. Exane Asset Management bought a new position in shares of Incyte Corporation in the second quarter valued at $126,000. Finally, Seven Eight Capital LP bought a new position in shares of Incyte Corporation in the second quarter valued at $129,000. 91.06% of the stock is currently owned by institutional investors.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.